CD20 blockers eye crowded rheumatology market

sea-maid submitted, created time 2 months 2 weeks (www.nature.com)

When trial results for a novel cancer drug were trumpeted in July, the rheumatology field felt the ripples. The drug is ofatumumab, a monoclonal antibody (mAb) targeting the CD20 molecule on B lymphocytes. Its makers, London-based GlaxoSmithKline (GSK) and Genmab of Copenhagen, announced that the mAb had met its primary and secondary endpoints in chronic lymphocytic leukemia (CLL)

1 comment | Blog It | Email It | Keywords: rheumatology immunology cancer ofatumumab GlaxoSmithKline CD20